FDA Updates Prescribing Information for PAH Treatment Winrevair
The U.S. Food and Drug Administration (FDA) has approved an update to the prescribing information for Merck's PAH treatment Winrevair (sotatercept-csrk).
The update specifies that Winrevair reduces the risk of serious complications, including hospitalization for PAH, lung transplant, and death, in adults with pulmonary arterial hypertension (PAH).
Winrevair was approved by the FDA last year to improve exercise capacity, improve World Health Organization (WHO) functional class, and reduce the risk of clinical worsening events in adults with PAH.
The new update provides clarification on the reduction of clinical worsening events.
Author's summary: FDA updates Winrevair's prescribing information.
More News
- Qualification system and 'road to' tool launched for World Athletics Ultimate Championship | News | Budapest 26 | World Athletics Ultimate Championships
- A pyrrhic budget victory could land Carney in the legislative hurt…
- PepsiCo Launches Protein-Focused Beverages to Meet Demand - Medical Herald
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- I didn’t miss the irony of Invisible Disabilities Week going unnoticed
- Why Israel Lost the Gaza Opinion War
- Chipotle’s Stock Plunges 18% On Lowered Guidance
- Spot the Anglican Irony - THE OTHER CHEEK
- Familial Clustering Identified in Primary Hyperparathyroidism